Related Experiment Video
Updated: Jun 27, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Parkinson's disease: emerging pharmacotherapy
Karl Strecker1, Johannes Schwarz
1Department of Neurology, University of Leipzig, Movement Disorders group, Liebigstrasse 22 a, 04103 Leipzig, Germany. Karl.Strecker@medizin.uni-leipzig.de
Expert Opinion on Emerging Drugs
|December 3, 2008
Summary
Parkinson's disease (PD) management faces challenges due to limited treatments and side effects. This review explores current therapies and future developments to improve the quality of life for PD patients.
Area of Science:
- Neurology
- Neurodegenerative Diseases
Background:
- Parkinson's disease (PD) is the second leading neurodegenerative disorder, affecting approximately 0.3% of the global population.
- Motor symptoms like tremor and rigidity, alongside psychiatric comorbidities such as dementia and depression, significantly impact patients' lives.
- Current treatments offer symptomatic relief but lack disease-modifying strategies, and long-term therapy presents challenges like motor complications and drug side effects.
Purpose of the Study:
- To review existing therapeutic approaches for Parkinson's disease.
- To discuss emerging strategies and future developments in PD treatment.
- To highlight the need for novel agents to improve long-term patient quality of life.
Main Methods:
- Literature review of current Parkinson's disease therapies.
- Analysis of challenges in long-term PD management.
- Exploration of potential future therapeutic avenues.
Main Results:
- Existing treatments primarily manage motor symptoms but do not halt disease progression.
- Dopaminergic therapy can lead to motor complications and side effects.
- Non-motor symptoms and psychiatric comorbidities are prevalent and require management.
Conclusions:
- There is a critical need for new therapeutic agents for Parkinson's disease.
- Future research should focus on disease-modifying strategies and managing non-motor symptoms.
- Advancements in therapy aim to sustain and improve the quality of life for individuals with Parkinson's disease.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...